The Choice Cannot Be Made Without Knowing the Pathogen
Without microbiological data identifying the causative organism and its resistance pattern, neither ertapenem nor Zerbaxa (ceftazidime-avibactam) can be definitively recommended—the decision must be driven by whether you are treating a 3rd-generation cephalosporin-resistant Enterobacterales (3GCephRE) versus carbapenem-resistant Enterobacterales (CRE) or resistant Pseudomonas.
Clinical Decision Algorithm
Step 1: Identify the Infection Type and Likely Pathogen
For a 76-year-old post-spine surgery patient, consider:
- Surgical site infection (skin/soft tissue or deep wound)
- Healthcare-associated pneumonia (if ventilated)
- Urinary tract infection (if catheterized)
- Bloodstream infection (if central lines present)
Step 2: Apply Resistance Pattern-Based Selection
If 3GCephRE is suspected or confirmed (ESBL-producing organisms):
Choose ertapenem 1
- The 2022 ESCMID guidelines explicitly state that for patients with 3GCephRE infections, ertapenem may be used instead of broader carbapenems (imipenem/meropenem)
- Critical stewardship principle: New beta-lactam/beta-lactamase inhibitors (BLBLI) like Zerbaxa "are reserved antibiotics for extensively resistant bacteria" and should be avoided for 3GCephRE due to stewardship considerations 1
- Ertapenem provides adequate coverage while preserving Zerbaxa for truly resistant organisms
If CRE is suspected or confirmed:
Choose Zerbaxa (ceftazidime-avibactam) 1
- For severe CRE infections, ESCMID conditionally recommends ceftazidime-avibactam if active in vitro (moderate/low quality evidence)
- Ertapenem will be ineffective against carbapenem-resistant organisms
If resistant Pseudomonas is suspected:
Choose Zerbaxa 1
- Ertapenem has no anti-pseudomonal activity
- Ceftazidime-avibactam provides coverage for difficult-to-treat Pseudomonas aeruginosa
Step 3: Account for Renal Impairment (CrCl ≈55 mL/min)
Both drugs require dose adjustment at this renal function:
Ertapenem dosing 2:
- Standard dose: 1g IV daily
- With CrCl 30-50 mL/min: reduce to 500mg IV daily
- With CrCl <30 mL/min or hemodialysis: 500mg IV daily (give supplemental 150mg after dialysis if within 6 hours)
Zerbaxa dosing 3:
- Standard dose: 1.5g (ceftolozane 1g/tazobactam 0.5g) IV every 8 hours
- With CrCl 30-50 mL/min: 750mg IV every 8 hours
- With CrCl 15-29 mL/min: 375mg IV every 8 hours
- Critical warning: Risk of adverse reactions increases with renal impairment; elderly patients require careful monitoring 3
Step 4: Consider Age-Related Factors
At 76 years old, this patient faces specific risks:
With Zerbaxa 3:
- Higher incidence of adverse events in patients ≥65 years
- Substantially excreted by kidney—increased toxicity risk with renal impairment
- CNS adverse effects (seizures, encephalopathy) reported with excessive exposure, especially in elderly with renal dysfunction 4, 5
- Recent case reports document involuntary convulsions and abnormal brain discharge when concentrations exceed safe thresholds 4
With Ertapenem 6:
- Real-world 2025 study in elderly (≥65 years) with complicated intra-abdominal infections showed comparable effectiveness to broader agents
- Once-daily dosing improves compliance and reduces nursing burden
- Exploratory subgroup analysis suggested potential benefit in 65-70 age group 6
Critical Pitfalls to Avoid
Do not use Zerbaxa empirically for routine post-surgical infections—this violates stewardship principles and selects for resistance 1
Do not underdose Zerbaxa in renal impairment—recent data show renal-adjusted dosing independently associated with 4.47-fold higher mortality in KPC-producing Klebsiella BSI (HR 4.47,95% CI 1.09-18.03, P=0.037) 7. However, overdosing causes CNS toxicity 4
Do not assume standard dosing works—both drugs have altered pharmacokinetics in critical illness. Volume of distribution for ceftazidime can increase to 35-50L (vs. package insert values), and avibactam to 38-51L 8, 9
Monitor for therapeutic failure with dose-adjusted regimens—if using reduced-dose Zerbaxa, consider therapeutic drug monitoring if available, targeting ceftazidime trough >20 mg/L and avibactam >4 mg/L 10, 9
Practical Recommendation for This Case
Start with ertapenem 500mg IV daily (adjusted for CrCl ≈55 mL/min) as empirical therapy for post-surgical infection, pending cultures 1, 2, 6. This approach:
- Provides adequate coverage for likely healthcare-associated pathogens including 3GCephRE
- Preserves Zerbaxa for confirmed resistant organisms
- Offers once-daily convenience in elderly patient
- Minimizes CNS toxicity risk compared to dose-adjusted Zerbaxa in this age/renal function combination
Escalate to Zerbaxa 750mg IV every 8 hours only if cultures confirm CRE, resistant Pseudomonas, or clinical failure on ertapenem with susceptibility data supporting the switch 1, 3.